Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 2018
July 17 2018 - 8:30AM
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth
diagnostics company, today announced that it plans to release
second quarter 2018 financial results prior to market open on
Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive
Officer, and Rick Altieri, Chief Financial Officer, will host a
conference call to review the Company's results at 8:00 a.m.
Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial
(855) 363-5047 for United States callers or +1 (484) 365-2897 for
international callers and reference confirmation code 9268558,
approximately ten minutes prior to start time. To access the live
audio webcast or subsequent archived recording, visit the Investor
Relations section of Oxford Immunotec's website at
www.oxfordimmunotec.com. The replay will be available on the
Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests
for the management of underserved immune-regulated conditions. The
Company's first product is the T-SPOT®.TB test, which is used to
test for tuberculosis infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and
Drug Administration, Europe, where it has obtained a CE mark, as
well as Japan and China. The Company's second product line is a
range of assays for tick-borne diseases, such as Lyme disease. The
Company is headquartered near Oxford, U.K. and in Marlborough,
Mass. Additional information can be found at
www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties, including statements about our anticipated
plans, objectives, and intentions, including effects on future
financial and operating results, prospects for sales of our
products and other statements that are not historical facts. The
forward-looking statements in this release are based on current
expectations, assumptions and data available as of the date of this
release and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements, including but
not limited to: decisions by regulatory authorities, hospitals and
other health care institutions, laboratories, physicians, patients
and third party payers that could affect the Company's business and
prospects; as well as our ability to expeditiously and successfully
expand our sales and distribution networks. The risks included
above are not exhaustive. Other factors that could adversely affect
our business and prospects are described under the "Risk Factors"
section in our filings with the Securities and Exchange Commission
("SEC"). Our filings are available for free by visiting the
investor section of our website, www.oxfordimmunotec.com, or the
SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and
uncertainties. Forward-looking statements contained herein are
based on current expectations and assumptions and currently
available data and are neither predictions nor guarantees of future
events or performance. You should not place undue reliance on
forward-looking statements contained herein, which speak only as of
the date of this release. We do not undertake to update or revise
any forward-looking statements after they are made, whether as a
result of new information, future events, or otherwise, except as
required by applicable law.
CONTACTS:
For Media and Investor Inquiries: Karen
KoskiVP, Strategy and Investor RelationsOxford ImmunotecTel: +1
(508) 556-1377kkoski@oxfordimmunotec.com
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Sep 2023 to Sep 2024